Log in

ASX:MDC - Medlab Clinical Stock Price, Forecast & News

-0.02 (-5.48 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: A$0.35
50-Day Range
MA: A$0.40
52-Week Range
Now: A$0.35
Volume89,097 shs
Average VolumeN/A
Market Capitalization$74.30 million
P/E RatioN/A
Dividend YieldN/A
Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is based in Alexandria, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 8188 0311



Sales & Book Value

Annual Sales$5.43 million
Cash FlowA$0.05 per share
Book ValueA$0.07 per share



Market Cap$74.30 million
Next Earnings DateN/A

Receive MDC News and Ratings via Email

Sign-up to receive the latest news and ratings for MDC and its competitors with MarketBeat's FREE daily newsletter.

Medlab Clinical (ASX:MDC) Frequently Asked Questions

What is Medlab Clinical's stock symbol?

Medlab Clinical trades on the ASX under the ticker symbol "MDC."

Has Medlab Clinical been receiving favorable news coverage?

Media headlines about MDC stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medlab Clinical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Medlab Clinical.

Who are some of Medlab Clinical's key competitors?

What other stocks do shareholders of Medlab Clinical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medlab Clinical investors own include MGC Pharmaceuticals (MXC), iSignthis (ISX), BOD Australia (BDA) and Auscann Group (AC8).

Who are Medlab Clinical's key executives?

Medlab Clinical's management team includes the folowing people:
  • Dr. Sean Michael Hall, MD, CEO & Director
  • Mr. Alan Dworkin, CFO & Company Sec.
  • Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip Nutr, Director of Medical Research
  • Dr. David A. Rutolo, Director of Science
  • Mr. Paul Vilner, Director of Commercial Operations

What is Medlab Clinical's stock price today?

One share of MDC stock can currently be purchased for approximately A$0.35.

How big of a company is Medlab Clinical?

Medlab Clinical has a market capitalization of $74.30 million and generates $5.43 million in revenue each year. View Additional Information About Medlab Clinical.

What is Medlab Clinical's official website?

The official website for Medlab Clinical is http://www.medlab.co/.

How can I contact Medlab Clinical?

The company can be reached via phone at 61 2 8188 0311.

MarketBeat Community Rating for Medlab Clinical (ASX MDC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  9 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  14
MarketBeat's community ratings are surveys of what our community members think about Medlab Clinical and other stocks. Vote "Outperform" if you believe MDC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel